Cell surface heparan sulfate proteoglycans and lipoprotein metabolism

Cellular and Molecular Life Sciences

Volumn 56, Issue 9-10, 1999, Pages 857-870

  Kolset, S O ^a   Salmivirta, M ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Apoproteins; Atherosclerosis; Heparan sulfate; Lipases; Lipoproteins; Proteoglycans

Indexed keywords

ANTITHROMBIN; APOLIPOPROTEIN B; APOLIPOPROTEIN E; CYTOKINE; GROWTH FACTOR; LIPOPROTEIN; LIPOPROTEIN RECEPTOR; PROTEOHEPARAN SULFATE; SUPEROXIDE DISMUTASE; TRIACYLGLYCEROL LIPASE;

ATHEROSCLEROSIS; CELL MIGRATION; CELL PROLIFERATION; CELL SURFACE; HUMAN; LIPOPROTEIN METABOLISM; MOLECULAR INTERACTION; NONHUMAN; PROTEIN TRANSPORT; REVIEW;

EID: 0032695942     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000180050031     Document Type: Review

References (137)

1. Kjellén L. and Lindahl U. (1991) Proteoglycans: Structures and interactions. Annu. Rev. Biochem. 60: 443-475
2. Gallagher J. T. (1989) The extended family of proteoglycans: Social residents of the pericellular zone. Curr. Opin. Cell Biol. 4: 766-771
3. Bernfield M., Kokenyesi R., Kato M., Hinkes M. T., Spring J., Gallo R. L. et al. (1992) Biology of the syndecans: A family of transmembrane heparan sulfate proteoglycans. Annu. Rev. Cell Biol. 8: 365-393
4. Salmivirta M. and Jalkanen M. (1995) Syndecan family of cell surface proteoglycans: Developmentally regulated receptors for extracellular effector molecules. Experientia 51: 863-872
5. Rosenberg R. D., Showorak N. W., Liu J., Schwartz J. J. and Zhang L. (1997) Heparan sulfate proteoglycans of the cardiovascular system: Specific structures emerge but how is synthesis regulated. J. Clin. Invest. 99: 2062-2070
6. Iozzo R. V. and Cohen I. (1993) Altered proteoglycan gene expression and the tumor stroma. Experientia 49: 447-455
7. Jackson D. G. (1997) Human leucocyte heparan sulphate proteoglycans and their roles in inflammation. Biochem. Soc. Trans. 25: 220-224
8. van der Woude F. J. and van Det N. F. (1997) Heparan sulfate proteoglycans and diabetic nephropathy. Experimental Nephrology 5: 180-188
9. Snow A. D. and Wight T. N. (1989) Proteoglycans in the pathogenesis of Alzheimer's disease and other amyloidoses. Neurobiology and Aging 10: 481-498
10. Camejo G., Hurt-Camejo E., Olsson U. and Bondjers G. (1993) Proteoglycans and lipoproteins in atherosclerosis. Curr. Opin. Lipidol. 4: 385-391
11. Wight T. (1995) The extracellular matrix and atherosclerosis. Curr. Opin. Lipidol. 6: 326-334
12. Bourin M-C. and Lindahl U. (1993) Glycosaminoglycans and the regulation of blood coagulation. Biochem. J. 289: 313-330
13. Camejo G., Hurt-Camejo E., Wiklund O. and Bonders G. (1998) Association of apoB lipoproteins with arterial proteoglycans: Pathological significance and molecular basis. Atherosclerosis 139: 205-222
14. Conrad, H. E. (1998) Heparin-Binding Proteins, Academic Press, San Diego
15. Mahley R. W. and Ji Z.-S. (1999) Remnant lipoprotein metabolism: Key pathways involving cell-surface proteoglycans and apolipoprotein E. J. Lipid. Res. 40: 1-16
16. Williams K. J. and Fuki I. V. (1997) Cell-surface heparan sulfate proteoglycans: Dynamic molecules mediating ligand catabolism. Curr. Opin. Lipidol. 8: 253-262
17. David G. (1993) Integral membrane heparan sulfate proteoglycans. FASEB J. 7: 1023-1030
18. Derynck R. and Feng X. H. (1997) TGF-beta receptor signaling. Biochim. Biophys. Acta 1333: 105-150
19. Underhill C. (1992) CD44: The hyaluronan receptor. J. Cell Sci. 103: 293-298
20. Carey D. J. (1997) Syndecans: Multifunctional cell-surface co-receptors. Biochem. J. 327: 1-16
21. Zimmermann P. and David G. (1999) The syndecans, tuners of transmembrane signaling. FASEB J. 13: 91-100
22. Woods A. and Couchman J. R. (1998) Syndecans:synergistic activators of cell adhesion. Trends Cell Biol. 8: 189-192
23. Asundi V. K. and Carey D. J. (1995) Self-association of N-syndecan (syndecan-3) core protein is mediated by a novel structural motif in the transmembrane domain and ectodomain flanking region. J. Biol. Chem. 270: 26404-26410
24. McFall A. J. and Rapraeger A. C. (1998) Characterization of the high affinity cell binding domain in the cell surface proteoglycan syndecan-4. J. Biol. Chem. 273: 28270-28276
25. Lander A. D., Stipp C. S. and Ivins J. K. (1996) The glypican family of heparan sulfate proteoglycans: Major cell-surface proteoglycans of the developing nervous system. Perspect. Dev. Neurobiol. 3: 347-358
26. Salmivirta M., Lidholt K. and Lindahl U. (1996) Heparan sulfate-a piece of information. FASEB J. 10: 1270-1279
27. Lindahl U., Kusche-Gullberg M. and Kjellén L. (1998) Regulated diversity of heparan sulfate. J. Biol. Chem. 273: 24979-24982
28. Maccarana M., Sakura Y., Tawada A., Yoshida K. and Lindahl U. (1996) Domain structure of heparan sulfates from bovine organs. J. Biol. Chem. 271: 17804-17810
29. Lindahl B., Eriksson L. and Lindahl U. (1995) Structure of heparan sulphate from human brain, with special regard to Alzheimer's disease. Biochem. J. 306: 177-184
30. Kojima T., Leone C. W., Marchildon G. A., Marcum J. A. and Rosenberg R. D. (1992) Isolation and characterization of heparan sulfate proteoglycans produced by cloned rat microvascular endothelial cells. J. Biol. Chem. 267: 4859-4869
31. Faham S., Hileman R. E., Fromm J. R., Linhardt R. J. and Rees D. C. (1996) Heparin structure and interactions with basic fibroblast growth factor. Science 271: 1116-1120
32. Feyzi E., Lustig F., Fager G., Spillmann D., Lindahl U. and Salmivirta M. (1997) Characterization of heparin and heparan sulfate domains binding to the long splice variant of platelet-derived growth factor A chain. J. Biol. Chem. 272: 5518-5524
33. Feyzi E., Trybata E., Bergström T., Lindahl U. and Spillmann D. (1997) Structural requirement of heparan sulfate for interaction with herpes simplex virus type 1 virions and isolated glycoprotein C. J. Biol. Chem. 272: 24850-24857
34. Rapraeger A. C., Krufka A. and Okwin B. B. (1991) Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation. Science 252: 1705-1708
35. Klaassen C. D. and Boles J. W. (1997) The importance of 3′-phosphoadenosine 5′-phosposulfate (PAPS) in the regulation of sulfation. FASEB J. 11: 404-418
36. Sen J., Goltz J. S., Stevens L. and Stein D. (1998) Spatially restricted expression of pipe in the Drosphila egg chamber defines embryonic dorsal-ventral polarity. Cell 95: 471-481
37. Bullock S. L., Fletcher J. M., Beddington R. S. P. and Wilson V. A. (1998) Renal agenesis in mice homozygous for a gene trap mutation in the gene encoding heparan sulfate 2-sulfotransferase. Genes Dev. 12: 1894-1906
38. Langford J. K., Stanley M. J., Cao D. and Sanderson R. D. (1998) Multiple heparan sulfate chains are required for optimal syndecan-1 function. J. Biol. Chem. 273: 29965-29971
39. Spillmann D., Witt D. and Lindahl U. (1998) Defining the interleukin-8-binding domain of heparan sulfate. J. Biol. Chem. 273: 15487-15493
40. Lortat-Jacob H., Turnbull J. E. and Grimaud J.-A. (1995) Molecular organization of the interferon-gamma-binding domain in heparan sulfate. Biochem. J. 310: 497-505
41. DeAgostini A. I., Watkins S. C., Slayter H. S., Youssoufian H. and Rosenberg R. (1990) Localization of anticoagulantly active heparan sulfate proteoglycans in vascular endothelium: Antithrombin binding on cultured endothelial cells and perfused rat aorta. J. Cell Biol. 111: 1293-1304
42. Zhang L., Schwartz J. J., Miller J., Liu J., Fritze L. M. S., Shworak N. W. et al. (1998) The retinoic acid and cAMP dependent up-regulation of 3-O-sulfotransferase-1 leads to a dramatic augmentation of anticoagulantly active heparan sulfate biosyntesis in F9 embryonal carcinoma cells. J. Biol. Chem. 273: 27998-28003
43. Ross R. (1993) The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 362: 801-809
44. Guimond S., Maccarana M., Olwin B. B., Lindahl U. and Rapracger A. C. (1993) Activating and inhibitory heparin sequences for FGF-2 (basic FGF). Distinct requirements for FGF-1, FGF-2 and FGF-4. J. Biol. Chem. 268: 23906-23914
45. Maccarana M., Casu B. and Lindahl U. (1993) Minimal sequence in heparin heparan sulfate required for binding of basic fibroblast growth factor. J. Biol. Chem. 268: 23898-23905
46. Pye D. A., Vives R. R., Turnbull J. E., Hyde P. and Gallagher J. T. (1998) Heparan sulfate oligosaccharides require 6-O-sulfation for promotion of basic fibroblast growth factor mitogenic activity. J. Biol. Chem. 273: 22936-22942
47. Lyon M., Deakin J. A., Mizuno K., Nakamura T. and Gallagher J. T. (1994) Interaction of hepatocyte growth factor with heparan sulfate: Elucidation of the major heparan sulfate structural determinants. J. Biol. Chem. 269: 11216-11223
48. Ashikari S., Habuchi H. and Kimata K. (1995) Characterization of heparan sulfate oligosaccharides that bind to hepatocyte growth factor. J. Biol. Chem. 270: 29586-29593
49. Parthasarathy N., Goldberg I. J., Sivaram P., Mulloy B., Flory D. M. and Wagner W. D. (1994) Oligosaccharide sequences of endothelial cell surface heparan sulfate proteoglycan with affinity for LPL. J. Biol. Chem. 269: 22391-22396
50. Ishihara M. (1994) Structural requirements in heparin for binding and activation of FGF-1 and FGF-4 are different from that for FGF-2. Glycobiology 4: 817-824
51. Kreuger J., Prydz K., Pettersson R. F., Lindahl U. and Salmivirta M. (1999) Characterization of fibroblast growth factor 1 binding heparan sulfate domain. Glycobiology 9: 723-729
52. Thurnbull J., Hopwood J. J. and Gallagher J. T. (1999) A strategy for rapid sequencing of heparan sulfate and heparin saccharides. Proc. Natl. Acad. Sci. USA 96: 2698-2703
53. Vivès R. R., Pye D. A., Salmivirta M., Hopwood J. J., Lindahl U. and Gallagher J. T. (1999) Sequence analysis of heparan sulphate and heparin oligosaccharides. Biochem J. 339: 767-773
54. Brickman Y. G., Ford M. D., Gallagher J. T., Nurcombe V., Bartlett P. F. and Turnbull J. E. (1998) Structural modification of fibroblast growth factor-binding heparan sulfate at a determinative stage of neural development. J. Biol. Chem. 273: 4350-4359
55. Salmivirta M., Safaiyan F., Prydz K., Andresen M. S., Aryan M. and Kolset S. O. (1998) Differentiation-associated modulation of heparan sulfate structure and function in CaCo-2 colon carcinoma cells. Glycobiology 8: 1029-1036
56. Feyzi E., Saldeen T., Larsson E., Lindahl U. and Salmivirta M. (1998) Age-dependent modulation of heparan sulfate structure and function. J. Biol. Chem. 273: 13395-13398
57. Winterbourne D. J. and Mora P. T. (1981) Cells selected for high tumorigenicity or transformed by simian virus 40 synthesize heparan sulfate with reduced degree of sulfation. J. Biol. Chem. 256: 4310-4320
58. Jayson G. C., Lyon M., Paraskeva C., Turnbull J. E., Deakin J. A. and Gallagher J. T. (1998) Heparan sulfate undergoes specific structural changes during the progression from human colon adenoma to carcinoma in vitro. J. Biol. Chem. 273: 51-57
59. Safaiyan F., Lindahl U. and Salmivirta M. (1998) Selective reduction of 6-O-sulfation in heparan sulfate from transformed mammary epithelial cells. Eur. J. Biochem. 252: 576-582
60. Ghiselli G., Lindahl U. and Salmivirta M. (1988) Foam cell conversion of macrophages alters the biosynthesis of heparan sulfate. Biochem. Biophys. Res. Commun. 247: 790-795
61. Kjellén L., Bielefeld D. and Höök M. (1983) Reduced sulfation of liver heparan sulfate in experimentally diabetic rats. Diabetes 32: 337-342
62. Lindahl B. and Lindahl U. (1997) Amyloid-specific heparan sulfate from human liver and spleen. J. Biol. Chem. 272: 26091-26094
63. Steinberg D. (1997) Low density lipoprotein oxidation and its pathobiological significance. J. Biol. Chem. 272: 20963-20966
64. Burgess J. W., Liang P., Vaidyanath C. and Marcel Y. L. (1999) ApoE of the HepG2 cell surface includes a major pool associated with chondroitin sulfate proteoglycans. Biochemistry 38: 524-531
65. Halvorsen B., Aas U. K., Kulseth M. A., Drevon C. A., Christiansen E. N. and Kolset S. O. (1998) Proteoglycans in macrophages: Characterization and possible role in the uptake of lipoproteins. Biochem. J. 331: 743-752
66. Jaye M, Lynch K. J., Krawiec J., Marchadíer D., Maugeais C., Doan K. et al. (1999) A novel endothelial-derived lipase that modulates HDL metabolism. Nature Genet. 4: 424-428
67. Goldberg I. J. (1996) LPL and lipolysis: Central roles in lipoprotein metabolism and atherogenesis. J. Lipid Res. 37: 693-707
68. Olivecrona T., Hultin M., Bergo M and Olivecrona G. (1997) LPL: Regulation and role in lipoprotein metabolism. Proc. Nutr. Soc. 56: 723-729
69. Beisiegel U. and Heeren J. (1997) LPL (E.C. 3.1.1.34) targeting of lipoproteins to receptors. Proc. Nutr. Soc. 56: 731-737
70. Lookene A., Chevreuil O., Østergaard P. and Olivecrona G. (1996) Interaction of LPL with heparin fragments and with heparan sulfate: Stoichiometry, stabilization, and kinetics. Biochemistry 35: 12155-12163
71. Berryman D. E. and Bensadoun A. (1995) Heparan sulfate proteoglycans are primarily responsible for the maintenance of enzyme activity, binding and degradation of LPL in Chinese hamster ovary cells. J. Biol. Chem. 270: 24525-24531
72. Liu G., Bengtsson-Olivecrona G. and Olivecrona T. (1993) Assembly of LPL in perfused guinea pig hearts. Biochem. J. 292: 277-282
73. Saxena U., Klein M. G. and Goldberg I. J. (1991) Transport of LPL across endothelial cells. Proc. Natl. Acad. Sci. USA 88: 2254-2258
74. Misra K. B., Kim K. C., Cho S., Low M. G. and Bensadoun A. (1994) Purification and characterization of adipocyte heparan sulfate proteoglycans with affinity for LPL. J. Biol. Chem. 269: 23838-23844
75. Pillarisetti S., Paka L., Sasaki A., Vanni-Reyes T., Yin B., Parthasarathy N. et al. (1997) Endothelial cell heparanase modulation of LPL activity. J. Biol. Chem. 272: 15753-15759
76. Olivecrona T., Chernick S. S., Bengtsson-Olivecrona G, Garrison M. and Crow R. O. (1987) Synthesis and secretion of LPL in 3T3-k1 adipocytes: Demonstration of inactive Forros of lipase in cells. J. Biol. Chem. 262: 10748-10759
77. Cisar L. A., Hoogewerf A. J., Cupp M., Rapport C. A. and Bensadoun A. (1989) Secretion and degradation of LPL in cultured adipocytes. Binding of LPL to membrane heparan sulfate is necessary for degradation. J. Biol. Chem. 264: 1767-1774
78. Saxena U., Klein M. G. and Goldberg I. J. (1990) Metabolism of endothelial cell-bound LPL: Evidence for heparan sulfate proteoglycan-mediated internalization and recycling. J. Biol. Chem. 265: 12880-12886
79. Chait A., Iverius P. H. and Brunzell J. D. (1982) LPL secretion by human monocyte-derived macrophages. J. Clin. Invest. 69: 490-493
80. Edwards I. J., Hongzhi X., Obunike J. C., Goldberg I. J. and Wagner W. D. (1994) Differentiated macrophages synthesize a heparan sulfate proteoglycan and an oversulfated chondroitin sulfate proteoglycan that bind LPL. Arterioscler. Thromb. Vasc. Biol. 15: 400-409
81. Hendriks W. L., van der Boom H., van Vark L. C. and Havekes L. M. (1996) LPL stimulates the binding and uptake of moderately oxidized low-density lipoprotein by J774 macrophages. Biochem. J. 314: 563-568
82. Olivecrona, T. and Bengtsson-Olivecrona, G. (1989) Heparin and lipases. In: Heparin, pp. 335-361, Lane D. and Lindahl U. (eds), Edward Arnold Publishers, London
83. Liu G., Hultin M., Ostergaard P. and Olivecrona T. (1992) Interaction of size-fractionated heparins with LPL and hepatic lipase in the rat. Biochem. J. 285: 731-736
84. Clarke A. R., Luscombe M. and Holbrook J. J. (1983) The effect of chain length of heparin on its interaction with LPL. Biochim. Biophys. Acta 747: 130-137
85. Larnkjær A., Nykjær A., Olivecrona G., Thøgersen H. and Østergaard P. B. (1995) Structure of heparin fragments with high affinity for LPL and inhibition of LPL binding to α2-macroglobulin-receptor/low density lipoprotein receptor-related protein by heparin fragments. Biochem. J. 307: 205-214
86. Schoonderwoerd K., Verhoeven A. J. and Jansen H. (1994) Rat liver contains a limited number of binding sites for heaptic lipase. Biochem. J. 302: 717-722
87. Persson B., Bengtsson-Olivecrona G., Enerbàck S., Olivecrona T. and Jørnvall H. (1989) Structural features of LPL. Lipase family relationships, binding interactions, non-equivalence of lipase co-factors, vitellogenin similarities and functional subdivision of LPL. Eur. J. Biochem. 179: 39-45
88. Berryman D. E. and Bensadoun A. (1993) Site-directed mutagenesis of a putative heparin-binding domain of avian LPL. J. Biol. Chem. 268: 3272-3276
89. van Tilbeurgh H., Roussel A., Laloul J.-M. and Cambillau C. (1994) LPL. Molecular model based on the pancreatic lipase X-ray structure: Consequences for heparin binding and catalysis. J. Biol. Chem. 269: 4626-4633
90. Sanan D. A., Fan J., Bensadoun A. and Taylor J. M. (1997) Hepatic lipase is abundant on both hepatocyte and endothelial surfaces in the liver. J. Lipid Res. 38: 1002-1013
91. Davis R. C., Wong H., Nikazy J., Wang K., Han Q. and Schotz M. C. (1992) Chimeras of hepatic lipase and LPL: Domain localization of enzyme-specific properties. J. Biol. Chem. 267: 21499-21504
92. Camps L., Reina M., Llobera M., Bengtsson-Olivecrona G., Olivecrona T. and Vilaro S. (1991) Liopoprotein lipase in lungs, spleen and liver: Synthesis and distribution. J. Lipid Res. 32: 1877-1888
93. Chappell D. A., Fry G. L., Waknitz M.A., Muhonen L. E., Pladet M. W., Iverius P. H. et al. (1993) Lipoprotein lipase induces catabolism of normal triglyceride-rich lipoproteins via the low density lipoprotein receptor related protein/alpha 2-macroglobulin receptor in vitro. A process facilitated by cell-surface proteoglycans. J. Biol. Chem. 268: 14168-14175
94. van Barlingen H. H., de Jong H., Erkelens D. W. and de Bruin T. W. (1996) Lipoprotein lipase-enhanced binding of human triglyceride-rich lipoproteins to heparan sulfate: Modulation by apolipoprotein E and apolipoprotein C. J. Lipid. Res. 37: 754-763
95. Choi S. Y., Fong L. G., Kirven M. J. and Cooper A. D. (1991) Use of ah anti-low density lipoprotein receptor antibody to quantify the role of the LDL receptor in the removal of chylomicron remnants in the mouse in vivo. J. Clin. Invest. 88: 1173-1181
96. Ji Z. S., Brecht W. J., Miranda R. D., Hussain M. M., Innerarity T. L. and Mahley R. W. (1993) Role of heparan sulfate proteoglycans in the binding and uptake of apolipoprotein E-enriched remnant lipoproteins by cultured cells. J. Biol. Chem. 268: 10160-10167
97. Ji Z.-S., Sanan D. A. and Mahley R. W. (1995) Intravenous heparinase inhibits remnant lipoprotein clearance from the plasma and uptake by the liver: In vivo role of heparan sulfate proteoglycans. J. Lipid. Res. 36: 583-592
98. Ji Z.-S., Dichek H. L., Miranda R. D. and Mahley R. W. (1997) Heparan sulfate proteoglycans participate in hepatic lipase and apolipoprotein E-mediated binding and uptake of plasma lipoproteins, including high density lipoproteins. J. Biol. Chem. 272: 31285-31292
99. Zeng B. J., Mortimer B. C., Martins I. J., Seydel U. and Redgrave T. G. (1998) Chylomicron remant uptake is regulated by the expression and function of heparan sulfate proteoglycan in hepatocytes. J. Lipid Res. 39: 845-860
100. Mulder M., Lombardi P., Jansen H., van Berkel T. J., Frants R. R. and Havekes L. M. (1993) Low density lipoprotein receptor internalizes low density and very low density lipoproteins that are bound to heparan sulfate proteoglycans via LPL. J. Biol. Chem. 268: 9369-9375
101. Al-Haideri M., Goldberg. I. J., Galaeano N. F., Gleeson A., Vogel T., Gorecki M. et al. (1997) Heparan sulfate proteoglycan-mediated uptake of apolipoprotein E-triglyceride-rich lipoprotein particles: A major pathway at physiological particle concentrations. Biochemistry 36: 12766-12772
102. Weisgraber K. H. and Rall S. C. Jr (1987) Human apolipoprotein B-100 heparin binding sites. J. Biol. Chem. 262: 11097-11103
103. Hirose N., Blankenship D. T., Krivanek M. A., Jackson R. L. and Cardin A. D. (1987) Isolation and characterization of four heparin-binding cyanogen bromide peptides of human plasma apolipoprotein B. Biochemistry 26: 5505-5512
104. Borén J., Olin K., Lee I., Chait A., Wight T. N. and Inerarity T. L. (1998) Identification of the principal proteoglycan-binding site in LDL. A single point mutation in apoB-100 severely affects proteoglycan interaction without affecting LDL receptor binding. J. Clin. Invest. 101: 2658-2664
105. 2-terminal region of apolipoprotein B is sufficient for lipoprotein association with glycosaminolgycans. J. Biol. Chem. 273: 35355-35361
106. Weisgraber K. H., Rall S. C. Jr, Mahley R. W., Milne R. W., Marcel Y. L. and Sparrow J. T. (1986) Human apolipoprotein E. Determination of the heparin binding site of apolipoprotein E3. J. Biol. Chem. 261: 2068-2076
107. Cardin A. D., Hirose N., Blankenship D. T., Jackson R. L. and Harmony A. K. (1986) Binding of a high reactive heparin to human apolipoprotein E: Identification of two heparin binding domains. Biochem. Biophys. Res. Commun. 134: 783-789
108. Innerarity T. L., Friedlander E., Rall S. C. Jr and Mahley R. W. (1983) The receptor-binding domain of human of human apolipoprotein E: Binding of apolipoprotein E fragments. J. Biol. Chem. 258: 12341-12347
109. Lalazar A., Ignatius S.-H. and Mahley R. W. (1986) Human apolipoprotein E receptor E: Receptor binding activity of truncated variants with carboxyl-terminal deletions. J. Biol. Chem. 264: 8447-8450
110. Ji Z. S., Fazio S. and Mahley R. W. (1994) Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipoproteinemia. J. Biol. Chem. 269: 13421-13428
111. Corder E. H., Saunders A. M., Strittmatter W. J., Schmechel D. E., Gaskell P. C., Small G. W. et al. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261: 921-923
112. Harr S. D., Hollister R., Hyman B. T. and Mendez A. J. (1996) Brain expression of apolipoproteins E, J and A-I in Alzheimer's disease. J. Neurochem. 66: 2429-2435
113. Winkler K., Scharnagl H., Tisljar U., Hoschützky H., Friedrich I., Hoffmann M. M. et al. (1999) Competition of Aβ amyloid peptide and apolipoprotein E for receptor-mediated endocytosis. J. Lipid Res. 40: 447-455
114. Hoeschen R. K. (1997) Oxidative stress and cardiovascular disease. Can. J. Cardiol. 13: 1021-1025
115. Sandstrøm J., Carlsson L., Marklund S. L. and Edlund T. (1992) The heparin-binding domain of extracellular superoxide dismutase C and the formation of variants with reduced heparin affinity. J. Biol. Chem. 267: 18205-18209
116. Sandstrøm J., Nilsson P., Karlsson K. and Marklund S. L. (1994) Ten-fold increase in human plasma extracellular superoxide dismutase content caused by a mutation in heparin-binding domain. J. Biol. Chem. 269: 19163-19169
117. Enghild J. J, Thøgersen I. B., Oury T. D., Valnickova Z., Højrup P. and Crapo J. D. (1999) The heparin-binding domain of extracellular superoxide dismutase is proteolytically processed intracellularly during biosynthesis. J. Biol. Chem. 274: 14818-14822
118. Karlsson K., Edlund A., Sandstrøm J. and Marklund S. L. (1993) Proteolytic modification of the heparin-binding affinity of extracellular superoxide dismutase. Biochem. J. 290: 623-626
119. Saxena U. and Goldberg I. J. (1994) Endothelial cells and atherosclerosis: Lipoprotein metabolism, matrix interactions, and monocyte recruitment. Curr. Opin. Lipidol. 5: 316-322
120. Uhlin-Hansen L., Eskeland T. and Kolset S. O. (1989) Modulation of the expression of chondroitin sulfate proteoglycan in stimulated human monocytes. J. Biol. Chem. 264: 14916-14922
121. Clasper S., Vekemans S., Fiore M., Plebanski M., Wordsworth P., David G. et al. (1999) Inducible expression of cell surface heparan sulfate proteoglycan syndecan-2 (fibroglycan) on human activated macrophages can regulate fibroblast growth factor action. J. Biol. Chem. 274: 24113-24123
122. Yeaman C. and Rapraeger A. C. (1993) Post-translational regulation of syndecan-1 expression by cAMP in peritoneal macrophages. J. Cell Biol. 122: 941-950
123. Norgard-Sumnicht K. and Varki A. (1993) Calcium-dependent heparin-like lignads for L-selectin in nonlymphoid endothelial cells. Science 261: 480-483
124. Guiffre L., Cordey A. S., Monai N., Tardy Y., Schapira M. and Spertini O. (1997) Monocyte adhesion to activated aortic endothelium: Role of L-selectin and heparan sulfate proteoglycans. J. Cell Biol. 136: 945-956
125. Norgard-Sumnicht K. and Varki A. (1995) Endothelial heparan sulfate proteoglycans that bind to L-selectin have glucosamine residues with unsubstituted amino groups. J. Biol. Chem. 270: 12012-12024
126. Terkeltaub R., Boisvert W. A. and Cutriss L. K. (1998) Chemokines and atherosclerosis. Curr. Opin. Lipidol. 9: 397-405
127. Tanaka Y., Adams D. H., Hubscher S., Hirano H., Siebenlist U. and Shaw S. (1993) T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-1β. Nature 361: 79-82
128. Weber K. S., von Hundelschausen P., Clark-Lewis I., Weber P. C. and Weber C. (1999) Differential immobilization and hierarchical involvement of chemokines in monocyte arrest and transmigration on inflamed endothelium in shear flow. Eur. J. Immunol. 29: 700-712
129. Mertens G., Cassiman J.-J., Van den Berghe H., Vermylens J. and David G. (1992) Cell surface proteoglycans from human vascular endothelial cells. J. Biol. Chem. 267: 20435-20443
130. Webb L. M. C., Ehrengruber M. U., Clark-Lewis I., Baggiolini M. and Rot A. (1993) Binding of heparan sulfate or heparin enhances neutrophil responses to interleukin 8. Proc. Natl. Acad. USA 90: 7158-7162
131. Jackson R. L., Busch S. J. and Cardin A. D. (1991) Glycosaminoglycans: Molecular properties, protein interactions and role in physiological processes. Physiol. Rev. 71: 481-539
132. Cardin A. D. and Weintraub H. J. R. (1989) Molecular modeling of protein-glycosaminoglycan interactions. Arteriosclerosis 9: 21-32
133. Oh E.-S., Woods A. and Couchman J. R. (1997) Multimerization of the cytoplasmic domain of syndecan-4 is required for its ability to activate protein kinase C. J. Biol. Chem. 272: 11805-11811
134. Saoncella S., Echtermeyer F., Denhez F., Nowlen J. K., Mosher D., Robinson S. D. et al. (1999) Syndecan-4 signals cooperatively with intergrins in a Rho-dependent manner in the assembly of focal adhesions and actin stress fibers. Proc. Natl. Acad. Sci. USA 96: 2805-2810
135. Brousseau M. E. and Hoeg J. M. (1999) Transgenic rabbits as models for atherosclerotic research. J. Lipid Res. 40: 365-370
136. Veniant M. M., Kim E., McCormick S., Boren J., Nielsen L. B., Raabe M. et al. (1999) Insights into apolipoprotein B biology from transgenic and gene-targeted mice. J. Nutr. 129: 451S-455S
137. Esko J. D. (1991) Genetic analyses of proteoglycan structure, functions and metabolism. Curr. Opin. Cell Biol. 3: 805-816